What Is Hemoglobin Structure Function And Clinical Significance

Understanding Hemoglobin: Core Concepts

The functional efficiency of hemoglobin arises from its hierarchical organization: primary structure (amino acid sequence), secondary structure (alpha-helices), tertiary structure (folded subunits), and quaternary structure (interactions between subunits). Each subunit contains a heme group—a porphyrin ring coordinating a central ferrous iron (Fe²⁺) atom, which binds O₂ reversibly. The iron’s high-spin to low-spin transition upon O₂ binding stabilizes the oxyhemoglobin (HbO₂) conformation, while allosteric interactions between subunits modulate oxygen affinity.

Chemical Structure and Subunit Composition

The heme group (C₃₄H₃₂FeN₄O₄) is the oxygen-binding site, where Fe²⁺ coordinates with O₂ via a reversible reaction:

Hb (deoxy) + O₂ ⇌ HbO₂ (oxy)

Physiological Functions Beyond Oxygen Transport

1. pH Buffering and the Bohr Effect
Hemoglobin acts as a critical buffer for hydrogen ions (H⁺), mitigating metabolic acidosis. The Bohr effect describes the inverse relationship between pH and O₂ affinity: acidosis (↓pH) shifts the oxygen dissociation curve rightward, reducing Hb’s O₂ affinity and enhancing O₂ unloading in tissues. This occurs via:

2. Nitric Oxide Regulation
Hb binds NO with high affinity (~1000× greater than O₂), acting as a NO scavenger and vasoregulator. Deoxyhemoglobin (Hb) reacts with NO to form nitrosylhemoglobin (Hb-NO), reducing NO bioavailability and promoting vasoconstriction. Conversely, oxyhemoglobin (HbO₂) releases NO, facilitating vasodilation—a mechanism critical in microcirculatory control and erectile function.

3. Carbon Dioxide Carriage
CO₂ is transported in blood via three mechanisms:

Hemoglobin Variants: Structural and Clinical Comparisons

Oxygen Dissociation Curve and Allosteric Modulation

1.

Hemoglobin Levels: Normal Ranges and Variations

The interpretation of hemoglobin levels must account for biological variability, as deviations can reflect compensatory mechanisms or underlying disorders. For instance, athletes may exhibit elevated hemoglobin due to erythropoiesis stimulation, whereas chronic diseases like kidney failure or malignancies often suppress erythropoietic activity. Misinterpretations, such as equating low hemoglobin exclusively with anemia, can lead to delayed or inappropriate interventions. Below, structured reference ranges and influencing factors are presented to support clinical decision-making.

Standard Hemoglobin Reference Ranges by Demographic Group

General Adult Reference Ranges (WHO/NHANES, 2020):

Men: 13.8–17.2 g/dL (138–172 g/L)

Women (non-pregnant): 12.1–15.1 g/dL (121–151 g/L)

Pregnant women (1st trimester): ≥11.0 g/dL (110 g/L); progressive decline to ≥10.5 g/dL (105 g/L) by term (WHO, 2016).

Newborns (0–4 weeks): 14.5–22.5 g/dL (145–225 g/L)

Infants (1–2 years): 11.0–14.0 g/dL (110–140 g/L)

Children (2–15 years): 11.0–16.0 g/dL (110–160 g/L), with gender divergence post-puberty.

Factors Influencing Hemoglobin Levels

Nutritional Deficiencies and Metabolic Disorders
Iron, vitamin B12, and folate are essential for hemoglobin synthesis. Deficiencies impair erythropoiesis, leading to microcytic (iron deficiency) or macrocytic (B12/folate deficiency) anemia. Chronic malnutrition or malabsorption (e.g., celiac disease) exacerbates these deficits. For example:

Chronic Diseases and Systemic Disorders
Pathologies that disrupt erythropoietin (EPO) production or red blood cell (RBC) survival often result in anemia of chronic disease (ACD). Key examples include:

Genetic Hemoglobinopathies
Inherited disorders alter hemoglobin structure or production, leading to hemolytic anemia or ineffective erythropoiesis. Notable conditions include:

Hemoglobin Adaptations in Athletes vs. Sedentary Individuals

Hemoglobin Comparison: Athletes vs. Sedentary Individuals

Parameter	Athletes (Endurance-Trained)	Sedentary Individuals
Hemoglobin Range	14.5–18.5 g/dL (men); 13.0–16.5 g/dL (women)	13.8–17.2 g/dL (men); 12.1–15.1 g/dL (women)
Mechanism	EPO-mediated erythropoiesis; plasma volume reduction ("hemoconcentration")	Baseline erythropoietic activity; no training stimulus
Potential Risks	Blood doping (recombinant EPO misuse); polycythemia vera (Hb >18.5 g/dL)	Increased susceptibility to anemia with acute illness
Clinical Thresholds	Hb >18.5 g/dL in men or >16.5 g/dL in women may indicate doping (WADA, 2021)	Hb <11.0 g/dL triggers anemia evaluation (WHO)

Risks of Blood Doping:

Common Misconceptions About Hemoglobin Levels

Misconception 1: "Low Hemoglobin Always Indicates Anemia"

Mis

Clinical Significance of Hemoglobin Abnormalities

Diagnostic Criteria and Classification of Anemia

Microcytic anemia typically reflects iron deficiency, thalassemia, or chronic disease. Iron deficiency, the most common cause, presents with low serum ferritin, elevated total iron-binding capacity (TIBC), and microcytic, hypochromic red blood cells (RBCs). Thalassemia, a hereditary hemoglobin disorder, is characterized by imbalanced globin chain synthesis (e.g., α-thalassemia or β-thalassemia), leading to ineffective erythropoiesis and hemolysis. Normocytic anemia often arises from acute blood loss, hemolytic anemia, or chronic kidney disease, where RBC production fails to compensate for losses. Macrocytic anemia is primarily associated with vitamin B12 or folate deficiency (megaloblastic anemia) or liver disease/alcoholism (non-megaloblastic macrocytosis).

Diagnostic Algorithm for Anemia Classification
1. Confirm anemia: Hemoglobin < lower limit of normal (age/sex-adjusted).
2. Assess MCV:

<80 fL → Microcytic (evaluate iron studies, hemoglobin electrophoresis).

80–100 fL → Normocytic (rule out hemolysis, chronic disease, or marrow failure).

>100 fL → Macrocytic (check B12/folate, liver function, reticulocyte count).

3. Further testing:

Microcytic: Serum ferritin, TIBC, hemoglobin electrophoresis (HbA2/HbF levels for thalassemia).

Normocytic: Reticulocyte count (high → hemolysis; low → marrow suppression).

Macrocytic: Serum B12, folate, methylmalonic acid (MMA), homocysteine.

Hemoglobinopathies: Genetic Mutations, Clinical Manifestations, and Treatment

Treatment approaches vary by severity:

Key Genetic and Clinical Features of Hemoglobinopathies

Disorder	Genetic Basis	Hemoglobin Involved	Clinical Features	Diagnostic Test
Sickle Cell Disease	HBB: Glu6Val (HbS)	HbS	VOCs, hemolytic anemia, splenic sequestration	Hb electrophoresis, genetic testing
β-Thalassemia Major	HBB: Nonsense/missense mutations	HbA2/HbF (δ/γ chains)	Severe anemia, hepatosplenomegaly, skeletal deformities	Hb electrophoresis, MCV <60 fL
HbC Disease	HBB: Glu6Lys (HbC)	HbC	Mild hemolytic anemia, target cells on smear	Hb electrophoresis (HbC migrates slower than HbA)
α-Thalassemia (HbH)	HBA1/HBA2 deletions (3 genes)	HbH (β4 tetramers)	Hemolytic anemia, splenomegaly	Hb electrophoresis, DNA analysis

Interpreting Hemoglobin Electrophoresis Results

Procedure for Electrophoretic Analysis:
1. Sample Preparation: Whole blood is lysed to release hemoglobin, which is then applied to a gel or cellulose acetate membrane.
2. Separation:

Electrophoretic Patterns in Common Hemoglobinopathies

Sickle Cell Trait (AS): HbA (~60%), HbS (~40%).

Sickle Cell Disease (SS): HbS (~90–95%), HbF (~5–10%), minimal HbA.

HbC Disease (CC): HbC (~90–95%), HbA (~5–10%

Hemoglobin in Medical Testing and Diagnostics

Hemoglobin (Hb) testing is a cornerstone of hematological diagnostics, providing critical insights into oxygen-carrying capacity, red blood cell (RBC) function, and underlying pathological conditions. Accurate measurement of hemoglobin requires meticulous pre-analytical handling, standardized methodologies, and integration with broader hematological panels such as the Complete Blood Count (CBC). This section explores the procedural protocols for sample collection and processing, compares automated and manual measurement techniques, and elucidates the diagnostic workflow for interpreting hemoglobin results within clinical contexts.

Step-by-Step Protocol for Blood Sample Collection and Processing

The reliability of hemoglobin measurements hinges on strict adherence to pre-analytical variables, including specimen collection techniques, anticoagulation, and storage conditions. Deviations in these parameters can introduce significant errors, leading to misdiagnosis or unnecessary investigations.

Pre-analytical Variables and Their Impact on Hemoglobin Testing
Pre-analytical errors account for up to 70% of laboratory testing discrepancies, with tourniquet application, anticoagulant selection, and sample stability being critical factors. For instance, prolonged tourniquet use (>1 minute) can cause hemoconcentration, falsely elevating hemoglobin levels by up to 5–10 g/dL, while improper anticoagulant ratios may lead to clotting or RBC lysis. Below are standardized steps to mitigate these variables:

1. Patient Preparation and Venipuncture
   • Ensure the patient is at rest for at least 15 minutes to avoid transient hemoconcentration due to exercise or stress.
   • Use a clean, sterile needle (21–23 gauge) and select a peripheral vein (e.g., median cubital or cephalic vein) to minimize trauma.
   • Avoid excessive probing or multiple punctures, which can cause hemolysis and artifactual hemoglobin release.
2. Tourniquet Application and Blood Draw
   • Apply the tourniquet no longer than 60 seconds before venipuncture to prevent venous stasis and hemoconcentration.
   • Release the tourniquet immediately after blood flow is established (typically within 10–15 seconds) to avoid RBC aggregation.
   • Discard the first 2–3 mL of blood to minimize contamination from tissue fluid or intravenous infusions.
3. Anticoagulant Selection and Sample Handling
   • Use ethylenediaminetetraacetic acid (EDTA) as the anticoagulant of choice for hemoglobin testing, as it preserves RBC morphology and prevents clotting without significantly altering hemoglobin concentration.
   • Fill the EDTA tube to at least 90% capacity (e.g., 2 mL in a 2.7 mL tube) to ensure proper anticoagulant-to-blood ratio (1:10–1:12).
   • Gently invert the tube 8–10 times to mix thoroughly, avoiding vigorous shaking to prevent hemolysis.
4. Sample Transport and Storage
   • Transport samples to the laboratory within 30 minutes of collection at room temperature (15–25°C) to prevent in vitro RBC lysis or glycolysis.
   • If delayed processing is unavoidable, refrigerate samples at 2–8°C for up to 24 hours; avoid freezing, as it disrupts RBC membranes.
   • Label specimens with patient details, collection time, and any relevant clinical notes (e.g., suspected hemolysis or polycythemia).

Critical Formulas and Reference Ranges

Hematocrit (Hct) Calculation: Hct (%) ≈ Hb (g/dL) × 3
(Note: This approximation assumes normal RBC mean corpuscular volume [MCV].)

Mean Corpuscular Hemoglobin Concentration (MCHC): MCHC (g/dL) = (Hb × 100) / Hct
(Normal range: 32–36 g/dL)

Automated vs. Manual Hemoglobin Measurement Methods

Hemoglobin quantification employs two primary methodologies: automated spectrophotometry and manual cyanmethemoglobin (HiCN) assays. Each method exhibits distinct advantages, limitations, and error profiles, influencing their applicability in clinical and point-of-care settings.

Comparison of Measurement Techniques

Parameter	Automated Spectrophotometry	Manual Cyanmethemoglobin (HiCN)
Principle	Measures light absorption at specific wavelengths (e.g., 540 nm for oxyhemoglobin) using multi-wavelength analyzers (e.g., Sysmex, Abbott Cell-Dyn).	Converts hemoglobin to cyanmethemoglobin (HiCN) via potassium ferricyanide and sodium cyanide, then measures absorbance at 540 nm.
Accuracy	±1 g/dL (high precision with internal quality controls); detects hemolysis, lipemia, and icterus via scatter plots.	±0.5 g/dL (gold standard for reference labs); susceptible to interference from high bilirubin or lipids.
Turnaround Time	30–90 seconds per sample (integrated into CBC analyzers).	10–15 minutes per batch (labor-intensive, not suitable for high-throughput labs).
Cost	High initial instrument cost ($20,000–$50,000); low per-test cost (~$1–$3).	Low initial cost (~$500–$1,000 for reagents); high per-test cost (~$5–$10).
Common Errors	False elevations due to cold agglutinins or hyperlipidemia. False lows from severe hemolysis or high WBC counts (interferes with light scatter).	Underestimation in thalassemia or HbC due to incomplete conversion to HiCN. Overestimation in methemoglobinemia (metHb) as it does not convert to HiCN.
Clinical Use	Routine CBC analysis, emergency settings, and large-scale screening.	Reference laboratories, research, and validation of automated results.

Interference and Correction Strategies
Automated systems employ flagging algorithms to identify potential interferences, such as:

Hemolysis: Reported as "H" flag; manual review of peripheral smear may reveal schistocytes or spherocytes.

Lipemia: Reported as "L" flag; repeat testing after fasting or using a plasma separator tube.

Icterus: Reported as "I" flag; consider direct bilirubin measurement if jaundice is suspected.

For manual HiCN assays, sodium dithionite can be added to correct for methemoglobin (metHb) interference by reducing it to hemoglobin.

Integration of Hemoglobin Testing into Complete Blood Count (CBC) Panels

Hemoglobin results are interpreted in conjunction with other CBC parameters to classify anemias, polycythemias, and RBC disorders. The RBC indices—mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and MCHC—provide a framework for differential diagnosis.

Reference Ranges and Diagnostic Integration

Normal CBC Reference Ranges (Adults)

Parameter

Range

Hemoglobin (Hb)

12–16 g/dL (female), 14–18 g/d Hemoglobin in Special Populations and Conditions Hemoglobin exhibits distinct adaptive and pathological variations across diverse physiological states, environmental exposures, and clinical conditions. These adaptations optimize oxygen transport efficiency in high-altitude populations, while pathological shifts—such as those observed in pregnancy, aging, or chronic disease—reflect underlying compensatory or maladaptive mechanisms. Understanding these variations is critical for tailored diagnostic and therapeutic approaches in clinical practice, particularly in populations where baseline hemoglobin parameters diverge from standard reference ranges. The study of hemoglobin in specialized contexts reveals both evolutionary advantages and clinical vulnerabilities. Genetic and physiological adaptations in high-altitude residents enhance oxygen affinity and delivery, whereas pregnancy-associated changes prioritize maternal-fetal oxygenation at the expense of maternal hemoglobin concentration. Elderly patients often present with anemia linked to chronic inflammation or medication interactions, while acute versus chronic blood loss triggers divergent compensatory pathways, including erythropoietin regulation and iron recycling. These distinctions underscore the need for population-specific hemoglobin assessment protocols. Hemoglobin Adaptations in High-Altitude Populations High-altitude environments (typically >2,500 meters above sea level) impose chronic hypoxic stress, driving evolutionary and physiological adaptations that optimize hemoglobin function. These adaptations primarily enhance oxygen unloading to tissues while maintaining adequate arterial oxygen saturation despite reduced atmospheric oxygen partial pressure (PaO₂). Genetic Adaptations: The EPAS1 gene (endothelial PAS domain protein 1), also known as HIF-2α, plays a central role in high-altitude adaptation. Polymorphisms in EPAS1 are associated with increased hemoglobin concentration and red blood cell mass in populations native to the Andes, Himalayas, and Ethiopian Highlands. For example: Andean populations: Higher hemoglobin levels (up to 20% above sea-level norms) are linked to EPAS1 variants that upregulate erythropoietin (EPO) production, improving oxygen-carrying capacity without excessive polycythemia. Tibetans: A distinct EPAS1 haplotype promotes efficient oxygen utilization at the tissue level, reducing the need for compensatory erythrocytosis. This "low-oxygen tolerance" phenotype minimizes hyperviscosity risks while maintaining adequate tissue oxygenation. Physiological Adaptations: Beyond genetic factors, high-altitude residents exhibit several physiological changes that modify hemoglobin function: Increased 2,3-Bisphosphoglycerate (2,3-BPG): Elevated levels in red blood cells (RBCs) reduce hemoglobin’s oxygen affinity (P₅₀ shift to the right), facilitating oxygen release to hypoxic tissues. Studies in Sherpas demonstrate 2,3-BPG concentrations up to 30% higher than sea-level controls. Higher RBC Count and Hemoglobin Concentration: Chronic hypoxia stimulates EPO secretion from the kidneys, leading to erythrocytosis. However, the magnitude varies by population: Andeans may develop hemoglobin levels of 18–20 g/dL, while Tibetans often maintain levels closer to 15–16 g/dL due to their distinct genetic adaptations. Enhanced Capillary Density: While not a direct hemoglobin adaptation, increased microvascular density in high-altitude natives improves oxygen extraction from blood, complementing hemoglobin’s role. Clinical Implications: High-altitude hemoglobin adaptations are not without risks. Excessive erythrocytosis can lead to chronic mountain sickness (Monge’s disease), characterized by symptoms such as cyanosis, dyspnea, and polycythemia vera-like features. Conversely, acute exposure to high altitudes (e.g., in lowlanders) may trigger acute mountain sickness (AMS), where hemoglobin’s oxygen-carrying capacity is overwhelmed by the sudden hypoxic challenge. These conditions necessitate individualized hemoglobin monitoring in high-altitude populations, particularly in athletes, pregnant women, or individuals with preexisting cardiovascular diseases. Hemoglobin Changes During Pregnancy Pregnancy induces significant hematological alterations to support the increased oxygen demands of the mother and fetus. These changes are primarily driven by hormonal shifts, plasma volume expansion, and iron requirements, often resulting in a physiological anemia that differs from pathological conditions. However, deviations from expected hemoglobin trajectories—either too low or too high—pose distinct clinical risks. Physiological Anemia of Pregnancy: Plasma Volume Expansion: During pregnancy, plasma volume increases by 40–50% to accommodate fetal growth and placental circulation. This hemodilution reduces hemoglobin concentration, even if red blood cell (RBC) mass remains stable. Hemoglobin levels typically decline to 10–11 g/dL in the second trimester, a condition known as dilutional anemia. Iron Requirements: Fetal development and placental growth demand additional iron, often exceeding dietary intake. Iron deficiency anemia (IDA) is common, with hemoglobin levels dropping below 10.5 g/dL in up to 40% of pregnancies in low-resource settings. Hormonal Influences: Elevated progesterone and estrogen levels suppress erythropoietin (EPO) production, further contributing to mild anemia. However, EPO levels rise in the third trimester to meet fetal demands. Risks of Excessive Hemoglobin Elevations: While physiological anemia is generally benign, elevated hemoglobin concentrations (>12 g/dL in the first trimester or >11 g/dL in later stages) warrant investigation. Potential causes and complications include: Hyperviscosity Syndrome: Hemoglobin levels >16 g/dL increase blood viscosity, impairing placental perfusion and raising risks of preeclampsia, fetal growth restriction (FGR), and stillbirth. Underlying conditions such as chronic hypertension, diabetes, or smoking may contribute. Gestational Diabetes and Obesity: These conditions are associated with higher hemoglobin levels due to insulin resistance and erythropoietin dysregulation, further exacerbating vascular complications. Paroxysmal Nocturnal Hemoglobinuria (PNH): Rare but critical to identify, as it presents with hemolytic anemia and elevated hemoglobin levels in some cases, requiring immediate intervention to prevent maternal-fetal morbidity. Diagnostic and Management Considerations: Hemoglobin Monitoring: Trimester-specific reference ranges are essential. For example, a hemoglobin <11 g/dL in the second trimester may indicate IDA, while persistent levels >12 g/dL require evaluation for underlying erythrocytosis or hyperviscosity. Iron Supplementation: Prophylactic iron (30–60 mg/day) is recommended for pregnant women, with adjustments based on ferritin levels. EPO Resistance: In cases of anemia refractory to iron, EPO levels should be assessed, as some pregnant women develop relative EPO deficiency due to hormonal suppression. Hemoglobin-Related Challenges in Elderly Patients Aging is associated with a progressive decline in hemoglobin levels, often termed age-related anemia (ARA), which differs from iron-deficiency anemia in younger adults. These changes stem from chronic inflammation, nutritional deficiencies, and age-related physiological declines in erythropoiesis. Additionally, polypharmacy in elderly patients introduces further complexities, as medications frequently interact with hemoglobin metabolism. Age-Related Anemia (ARA) and Pathophysiology: Decreased Erythropoietin (EPO) Production: Kidney function declines with age, reducing EPO secretion by 1–2% per year after age 30. This contributes to normocytic, normochromic anemia (hemoglobin typically 12–13 g/dL in men, 11–12 g/dL in women). Chronic Inflammation (Anemia of Inflammation): Elevated inflammatory cytokines (e.g., IL-6, TNF-α) suppress erythropoiesis and iron recycling. Conditions like osteoarthritis, heart failure, or chronic obstructive pulmonary disease (COPD) are common comorbidities. Nutritional Deficiencies: Poor dietary intake, malabsorption (e.g., due to atrophic gastritis or celiac disease), and reduced vitamin B12/folate absorption contribute to megaloblastic anemia in up to 20% of elderly anemic patients. Medication-Induced Hemoglobin Dysregulation: Elderly patients are particularly vulnerable to drug-related hemoglobin abnormalities due to: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Chronic use impairs renal EPO production and increases gastrointestinal blood loss, leading to normocytic anemia or iron deficiency. Chemotherapy: Myelosuppression from agents like carboplatin or 5-fluorouracil causes aplastic anemia or hemolytic anemia in cancer patients. Angiotensin-Converting Enzyme (ACE) Inhibitors: Rarely, these drugs induce hemolytic anemia in patients with underlying G6PD deficiency or autoimmune hemolysis. Proton Pump Inhibitors (PPIs): Long-term use may reduce gastric acidity, impairing vitamin B12 absorption and leading to pernicious anemia. Clinical Presentation and Diagnostic Approach: Elderly patients with anemia often present with fatigue, cognitive decline, or decompensated heart failure rather than classic symptoms like dyspnea. Key diagnostic steps include: CBC with Reticulocyte Count: Differentiates between hypoproliferative (low reticulocytes) and Hemoglobin emerges not merely as a passive oxygen carrier but as a dynamic biomolecule central to human survival, disease pathogenesis, and adaptive physiology. From the molecular intricacies of its subunits to the clinical ramifications of its dysregulation, this protein exemplifies the intersection of biochemistry, genetics, and medicine. Understanding its normal ranges, pathological deviations, and diagnostic applications equips clinicians with tools to refine patient management, while its evolutionary adaptations highlight nature’s ingenuity in optimizing oxygen delivery. As research continues to unravel hemoglobin’s broader functions—such as its role in nitric oxide signaling and chronic disease—its significance transcends traditional boundaries, reinforcing its status as a linchpin in both basic science and clinical practice. FAQ What is hemoglobin A1c and why is it important? Hemoglobin A1c (HbA1c) is a blood test that measures your average blood sugar levels over the past 2–3 months. It reflects how well diabetes is being managed, as glucose binds to hemoglobin in red blood cells. A normal range is typically 4%–5.6%, while levels ≥6.5% indicate diabetes. What is the normal hemoglobin range for adults? The normal hemoglobin range varies by age and sex: 12–15.5 g/dL for adult women and 13.5–17.5 g/dL for adult men. Lower levels may signal anemia, while higher levels could indicate dehydration or conditions like polycythemia. What does a hemoglobin level indicate about my health? Hemoglobin measures the oxygen-carrying protein in red blood cells. Low levels (anemia) can cause fatigue, weakness, or shortness of breath, while high levels may increase blood viscosity, raising risks of clots or stroke. It’s often tested as part of a complete blood count (CBC). What is the hemoglobin test used to diagnose? The hemoglobin test helps diagnose anemia, monitor chronic diseases (like kidney disease or diabetes), screen for blood disorders (e.g., thalassemia, sickle cell), and evaluate response to treatments like chemotherapy or iron supplements. How is the hemoglobin A1c test different from a regular hemoglobin test? The hemoglobin A1c test specifically measures long-term blood sugar control by assessing glucose attached to hemoglobin, while a regular hemoglobin test measures the total amount of hemoglobin in red blood cells. A1c is key for diabetes management; hemoglobin tests assess oxygen-carrying capacity. What does my hemoglobin count tell me about my red blood cells? Your hemoglobin count reflects how much oxygen your red blood cells can carry. A high count may mean excess red blood cells (polycythemia) or dehydration, while a low count often points to anemia or blood loss. It’s part of a CBC and helps identify underlying health issues. anemia diagnostics clinical hematology hemoglobin hemoglobinopathies oxygen transport Leave a Comment Name Comment Post Comment Comments are moderated before appearing. The data you submit is processed according to the Privacy Policy of Voltefac.